Survival outcomes
multiple myeloma
MULTIPLE MYELOMA, ONCOLOGY
The median follow‐up time was 20.8 months for the entire cohort. The median PFS was 24.5 months (95% Confidence interval [CI] 18.2–30.7) and the median OS was not reached, while the estimated 24‐month OS rate was 75.4%. At the time of analysis, 67 (42.1%) patients had progressed, and 34 (21.4%) had died in total.The median PFS of the Bd, Bd + X, and Rd regimens for the elderly NDMM patients were 24.9 months (95% CI 17.3–32.4), 24.4 months (95% CI 10.8–38.1), and not reached, respectively (Progression‐free survival and overall survival for the elderly multiple myeloma patients grouped according to different factors.The analysis of potential risk factors for PFS and OS in the whole cohort was conducted by the Kaplan–Meier method and Cox proportional hazards model (Figure Univariate and multivariate analyses of risk factors for PFS and OS
Abbreviations: Bd, bortezomib/dexamethasone; ECOG, Eastern Cooperative Oncology Group; OS, overall survival; PFS, progression‐free survival; PR, partial response; Rd, lenalidomide/dexamethasone.